Terms: = Lung cancer AND TPM4, P67936, 7171, ENSG00000167460 AND Treatment
4 results:
1. Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition.
Tian J; Wang V; Wang N; Khadang B; Boudreault J; Bakdounes K; Ali S; Lebrun JJ
Breast Cancer Res; 2021 Feb; 23(1):23. PubMed ID: 33588911
[TBL] [Abstract] [Full Text] [Related]
2. Lorlatinib for the treatment of inflammatory myofibroblastic tumour with tpm4-ALK fusion following failure of entrectinib.
Wong HH; Bentley H; Bulusu VR; Anyaegbu G; Watkins J; Horan G; Hatcher H
Anticancer Drugs; 2020 Nov; 31(10):1106-1110. PubMed ID: 32868646
[TBL] [Abstract] [Full Text] [Related]
3. ALKoma: a cancer subtype with a shared target.
Mano H
Cancer Discov; 2012 Jun; 2(6):495-502. PubMed ID: 22614325
[TBL] [Abstract] [Full Text] [Related]
4. Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: a retrospective European multi-center analysis.
Koscielniak E; Rodary C; Flamant F; Carli M; Treuner J; Pinkerton CR; Grotto P
Med Pediatr Oncol; 1992; 20(3):209-14. PubMed ID: 1574030
[TBL] [Abstract] [Full Text] [Related]
